Jianjun Zhang

Jan 6, 2025 | nature.com | Jianjun Zhang

AbstractImmune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit.

Dec 16, 2024 | nature.com | Jianjun Zhang

AbstractAlthough phytoestrogens modulated pancreatic tumour growth in experimental studies, it remains unclear whether phytoestrogen intake is associated with pancreatic cancer. Of 92,278 persons who completed the Diet History Questionnaire in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, 346 were diagnosed with pancreatic cancer within a median follow-up of 9.4 years.

Oct 30, 2024 | mdpi.com | Yuchen Zhang |Jianghong Zhu |Ke Wang |Jianjun Zhang

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Oct 4, 2024 | nature.com | Junya Fujimoto |Andrew Futreal |John Heymach |Jia Huang Wu |Christopher I. Amos |Jianjun Zhang

AbstractLung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of expression-based prognostic models.